


Melanoma and Skin Cancer Program

www.ucsfhealth.org/melanoma



BEST IN NORTHERN CALIFORNIA

UCSF Medical Center is best in Northern California for cancer care

NEW targeted therapy and immunotherapy treatments started in 2011




800+
PATIENTS SEEN ANNUALLY

RECOMMENDATION

96.7% ★★★★★

Patients who are likely to recommend the Melanoma and Skin Cancer Program to friends and family*

Change in overall survival for unresectable stage III-IV melanoma †



HOW TO REFER A PATIENT

STAGE I AND II MELANOMA

Dermatology

Phone: 415-353-7817

Fax: 415-353-7893

STAGE III AND IV MELANOMA

Medical Oncology

Phone: 415-353-7022

or 415-353-9900

Fax: 415-885-3802

Questions

Phone: 415-514-6382

(Nurse Navigator:

Ann Tittiger, RN)

Fax: 415-885-3802

HIGHLY SPECIALIZED CARE FOR PATIENTS WITH MELANOMA, MERKEL CELL AND OTHER SKIN CANCERS

As the top cancer center in Northern California, and among the top 12 in the nation, we confront cancer through scientific discovery and leading-edge medicine, guided by the principles of compassionate, patient-centered care.

- We provide advanced care for patients with all stages of melanoma, from early-stage melanomas to advanced metastatic cancer, as well as other types of skin cancer.
- We care for patients who are at higher risk of developing melanoma due to their family history, genetic mutations or the presence of abnormal moles.
- We are dermatologists, medical and surgical oncologists, radiation oncologists and dermatopathologists, all specializing in the diagnosis and treatment of skin cancer.

PATIENTS TREATED

- We treat patients with locoregionally advanced and metastatic melanoma and nonmelanoma skin cancers.
- Those at high risk for advanced disease are followed closely by a multidisciplinary team, including medical oncologists and dermatologists.

MORE →

* The Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS), Press Ganey, 2017.

† Albertini, Mark R. (2018, Aug. 22). The age of enlightenment in melanoma immunotherapy. Journal for ImmunoTherapy of Cancer. Retrieved from <https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0397-8>

WHY REFER TO UCSF?

- UCSF physicians have pioneered the development of PD-1 and BRAF/MEK inhibitors for melanoma and Merkel cell cancer
- Leading experts in immunotherapy and targeted therapy of melanoma and Merkel cell cancer
- Clinical trials with novel immunotherapy, gene therapy and targeted therapy including trials for PD-1-resistant patients, local recurrence, NRAS-mutant patients and trials for patients with Merkel cell, squamous cell and basal cell cancer
- Close collaboration through a melanoma tumor board with specialists from radiology, pathology, surgery, radiation oncology and immunology
- Full spectrum of skin diseases and cancers are treated in collaboration with the UCSF Dermatologic Surgery and Laser Center
- Specialized evaluation of the histological material from patients' primary melanoma, which is instrumental in determining the risk of recurrence and integrated into our treatment recommendations
- A specialized Pigmented Lesions/Melanoma Surveillance Clinic maps and tracks patients with multiple moles

CLINICAL TRIALS

Ten to 20 active melanoma clinical trials are ongoing at any given time. For a complete list, visit clinicaltrials.ucsf.edu.

OUR TEAM

Dermatology

Susana Ortiz-Urda, MD, PhD, MBA
Maria Wei, MD, PhD

Dermatologic Surgery

Sarah Arron, MD, PhD
Roy Grekin, MD
Isaac Neuhaus, MD
Siegrid Yu, MD

Dermatopathology

Philip LeBoit, MD
Tim McCalmont, MD
Jeffrey North, MD
Iwei Yeh, MD, PhD

Head and Neck Surgical Oncology

Patrick K. Ha, MD

Medical Oncology

Adil Daud, MD
Katy K. Tsai, MD

Melanoma Surgical Oncology

Michael D. Alvarado, MD, MS
Jonathan R. George, MD

Plastic and Reconstructive Surgery

Hani Sbitany, MD
Rahul Seth, MD

Radiation Oncology

Sue Yom, MD, PhD